November 25, 2017 3:38 AM ET

Biotechnology

Company Overview of 3-V Biosciences, Inc.

Key Executives for 3-V Biosciences, Inc.

NameBoard RelationshipsTitleAge
Merdad V. Parsey M.D., Ph.D.12 RelationshipsChief Executive Officer, President and Director--
Urs Greber Ph.D.No RelationshipsCo-Founder--
David M. Mott 209 RelationshipsExecutive Chairman51
Lucas Pelkmans Ph.D.No RelationshipsCo-Founder--
Rekha Hemrajani No RelationshipsChief Financial Officer and Senior Vice President of Business & Financial Operations--
View More Key Executives

3-V Biosciences, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
David M. Mott 209 RelationshipsMersana Therapeutics, Inc.51
Merdad V. Parsey M.D., Ph.D. 12 Relationships3-V Biosciences, Inc.--
Ed Harlow Jr., Ph.D. 12 Relationships3-V Biosciences, Inc.--
Robert J. Garland M.D. 46 RelationshipsNew Enterprise Associates--
Joseph D. Puglisi Ph.D. 22 RelationshipsPTC Therapeutics, Inc.--
View All Board Members

3-V Biosciences, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Advisory Board Jr., Ph.D.Ed Harlow12 Relationships6 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
389.1K
Bonus
242.6K
Total Short Term Compensation
486.4K
Total Value of Options
17.8M
Compensation as of Fiscal Year
3-V Biosciences, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Joshua Brumm Resigns as Chief Operating Officer and Chief Financial Officer of Versartis, Inc
November 22, 2017 10:06 PM ET
dorsaVi Limited Appoints Caroline Elliott as Independent Non Executive Director and as the Chair of the Audit and Risk Committee, Effective November 24, 2017
November 22, 2017 9:49 PM ET
OncoCyte Corporation Announces Resignation of Don M. Bailey as Director
November 22, 2017 9:40 PM ET
BONESUPPORT HOLDING AB (publ) Announces Appointment of Nomination Committee
November 22, 2017 5:30 PM ET
Repligen Corporation Announces Retirement of Howard Benjamin as Vice President of Business Development and Executive Officer
November 22, 2017 12:36 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3-V Biosciences, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.